

Clinical trials of Bupropion

TrialResults-center www.trialresultscenter.org

1 obesity and overweight

Trial	Treatments	Patients	Trials design and methods
Bupropion vs placebo			
Anderson , 2002 n=105/112 follow-up: 24 weeks	bupropion SR 300, or 400 mg/d. versus placebo	obese adults	double-blind
Croft , 2002 n=210/213 follow-up: 44 weeks	Bupropion, 300 mg for 44 wk versus Placebo	patients with major depression responder to open-label treatment with bupropion SR	double-blind
Jain , 2002 n=213/209 follow-up: 26 weeks	bupropion SR 300 mg/d versus Placebo	Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30)	double-blind

More details and results :

- All mechanism for obesity and overweight in all type of patients at <http://www.trialresultscenter.org/go-Q265>

References

Anderson, 2002:

Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. *Obes Res* 2002 Jul;10:633-41 [[12105285](#)]

Croft, 2002:

Croft H, Houser TL, Jamerson BD, Leadbetter R, Bolden-Watson C, Donahue R, Metz A Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. *Clin Ther* 2002 Apr;24:662-72 [[12017410](#)]

Jain, 2002:

Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. *Obes Res* 2002 Oct;10:1049-56 [[12376586](#)]